Table 1.
Univariate analysis regarding demographics and clinical characteristics of COVID-19 patients treated with remdesivir or not.
| Variable | Control Group n = 113 (%) |
Remdesivir n = 294 (%) |
p-Value |
|---|---|---|---|
| Male sex | 70 (62%) | 250 (80%) | <0.001 |
| Age, years, mean (± SD) | 62.5 (±20) | 63.2 (±15.3) | 0.717 |
| Days from symptoms/positive nasopharyngeal swab to admission, mean (± SD) | 4.5 (±4.3) | 5.3 (±3.8) | 0.084 |
| Charlson comorbidity index (± SD) | 2.5 (±2.1) | 2.6 (±1.9) | 0.719 |
| Cardiovascular disease | 17 (15%) | 33 (11%) | 0.203 |
| COPD | 19 (17%) | 31 (10%) | 0.051 |
| Chronic kidney disease | 10 (9%) | 18 (6%) | 0.256 |
| Liver cirrhosis | 2 (2%) | 12 (4%) | 0.293 |
| Diabetes mellitus | 21 (19%) | 53 (17%) | 0.672 |
| Solid lung cancer (primary or metastasis) | 1 (1%) | 3 (1%) | 1 |
| Fever | 56 (50%) | 246 (79%) | <0.001 |
| Cough | 33 (29%) | 157 (50%) | <0.001 |
| Dyspnea | 42 (37%) | 178 (57%) | <0.001 |
| Gastrointestinal symptoms (diarrhea, abdominal discomfort, nausea, vomiting) | 16 (14%) | 58 (18%) | 0.271 |
| Fatigue | 21 (19%) | 57 (19%) | 1 |
| Arthralgia/myalgia | 13 (12%) | 45 (14%) | 0.46 |
| Anosmia | 3 (3%) | 9 (3%) | 1 |
| Conjunctivitis | 0 (0%) | 2 (1%) | 0.397 |
| Chest pain | 5 (4%) | 11 (3%) | 0.655 |
| Parenchymal thickening | 72 (64%) | 232 (74%) | 0.046 |
| Interstitial lung disease | 16 (14%) | 15 (5%) | <0.001 |
| Pleural effusion | 20 (18%) | 26 (9%) | 0.012 |
| Bronchiectasis/emphysema | 27 (24%) | 50 (15%) | 0.032 |
| White blood cells ×103/uL, mean (±SD) | 7.38 (±3.59) | 8.06 (±5.99) | 0.287 |
| Neutrophils ×103/uL, mean (±SD) | 5.60 (±3.61) | 6.31 (±5.31) | 0.211 |
| Lymphocytes ×103/uL, mean (±SD) | 1.18 (±0.65) | 1.12 (±2.28) | 0.769 |
| Platelets ×103/uL, mean (±SD) | 247.66 (±100.85) | 218.47 (±81.73) | 0.004 |
| D-dimer ng/mL, mean (±SD) | 1365.71 (±1456.18) | 814.91 (±766.45) | <0.001 |
| Ferritin ng/mL, mean (±SD) | 692.35 (±942.17) | 645.02 (±489.52) | 0.591 |
| Procalcitonin ng/mL, mean (±SD) | 1.20 (±6.4) | 0.61 (±3.73) | 0.334 |
| LDH mU/mL, mean (±SD) | 288.46 (±163.73) | 302.37 (±119.57) | 0.3 |
| CPK U/L, mean (±SD) | 278.90 (±1430.63) | 149.47 (±161.35) | 0.17 |
| Lactates mmol/L, mean (±SD) | 1.57 (±0.36) | 1.33 (±0.83) | 0.328 |
| C-reactive protein mg/dL, mean (±SD) | 4.91 (±6.61) | 8.23 (±21.13) | 0.116 |
| PaO2/FiO2, mean (±SD) | 315.67 (±117.14) | 329.94 (±98.36) | 0.411 |
| Aspartate transaminase U/L, mean (±SD) | 34.16 (±47.76) | 35.24 (±27.41) | 0.784 |
| Alanine transaminase U/L, mean (±SD) | 32.20 (±28.42) | 33.24 (±28.84) | 0.755 |
Legend. SD, standard deviation; COPD, chronic obstructive pulmonary disease; LDH, lactate dehydrogenase; CPK, creatine phosphokinase.